Trials / Not Yet Recruiting
Not Yet RecruitingNCT06679673
SHR-1701 Combined with SHR2554 and BP102 for MCRC
An Explorative Study of SHR-1701 Combined with SHR2554 and BP102(bevacizumab) for Metastatic Colorectal Cancer.
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Response to oncologic treatment in mCRC is currently limited.
Detailed description
This is a single-center, open-labeled study exploring the efficacy and safety of SHR-1701 combined with SHR2554 and BP102 in the treatment of metastatic colorectal cancer (mCRC) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 | SHR-1701 |
| DRUG | BP102 | BP102 |
| DRUG | SHR2554 | SHR2554 |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2024-11-07
- Last updated
- 2024-11-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06679673. Inclusion in this directory is not an endorsement.